Drug Trial Radar · NCT02674152
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Jan 5, 2016
Primary completion
Sep 12, 2018
Study completion Nov 4, 2020
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously. The eligible patient population will be patients with advanced solid tumours. At any time during the trial, it will not be permitted to escalate to a dose which does not fulfil the escalation with overdose control (EWOC) criterion
Conditions
- Neoplasms
Interventions
BI 836880Drug
BI 836880
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: Up to 3 weeks after the first administration of trial medication.
- Number of Patients With Dose-limiting Toxicities (DLT) in the Maximum Tolerated Dose (MTD) PeriodTime frame: Up to 3 weeks after the first administration of trial medication.
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
INS Curie
Paris, France
Universitätsklinikum Augsburg
Augsburg, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.